Independent Solutions Wealth Management LLC Sells 430 Shares of Pfizer Inc. (NYSE:PFE)

Independent Solutions Wealth Management LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,994 shares of the biopharmaceutical company’s stock after selling 430 shares during the quarter. Independent Solutions Wealth Management LLC’s holdings in Pfizer were worth $608,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Birmingham Capital Management Co. Inc. AL increased its position in shares of Pfizer by 2.7% in the third quarter. Birmingham Capital Management Co. Inc. AL now owns 186,650 shares of the biopharmaceutical company’s stock valued at $5,402,000 after acquiring an additional 4,887 shares during the period. Copley Financial Group Inc. bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $577,000. Logan Capital Management Inc. increased its stake in shares of Pfizer by 2.7% during the third quarter. Logan Capital Management Inc. now owns 580,545 shares of the biopharmaceutical company’s stock valued at $16,801,000 after buying an additional 15,160 shares during the period. Inspire Trust Co. N.A. lifted its stake in Pfizer by 19.1% in the third quarter. Inspire Trust Co. N.A. now owns 92,708 shares of the biopharmaceutical company’s stock worth $2,683,000 after acquiring an additional 14,891 shares during the period. Finally, Peapack Gladstone Financial Corp increased its position in Pfizer by 23.9% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 762,976 shares of the biopharmaceutical company’s stock valued at $22,082,000 after purchasing an additional 147,405 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Guggenheim lowered their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Citigroup began coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.14.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Stock Down 0.7 %

Pfizer stock traded down $0.19 during midday trading on Thursday, hitting $25.70. 26,496,166 shares of the company’s stock were exchanged, compared to its average volume of 38,618,578. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $145.64 billion, a PE ratio of 34.73, a P/E/G ratio of 0.63 and a beta of 0.65. The firm has a 50-day moving average of $26.95 and a two-hundred day moving average of $28.22.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.17) earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.69%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 232.43%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.